Abstract
Introduction Malaria is still a major health problem in sub-Saharan Africa, where 98% of global malaria mortality occurs. In addition, the spread of Plasmodium falciparum with partial artemisinin resistance in East Africa and beyond is a great concern. The establishment of more effective vector control, in addition to the current long-lasting insecticide-treated net (LLIN) distribution program, is an urgent task in these areas. One novel vector control candidate is the Olyset®Plus ceiling nets which can overcome the problems of variations in net use behaviors and metabolic resistance to insecticide in vectors. Our preliminary study suggests the protective efficacy and high acceptability of this tool. With this proposed second trial, we aim to evaluate the impact of this tool in a different eco-epidemiological setting in the lake endemic region of Kenya.
Methods A cluster randomized controlled trial is designed to evaluate the impact of Olyset®Plus ceiling nets in Ndhiwa Sub-County, Homa Bay County, Kenya. A total of 44 clusters will be randomly assigned in a 1:1 ratio to the intervention group (Olyset®Plus ceiling nets) and the control group. The assignment will be accomplished through covariate-constrained randomization of clusters. For the primary outcome of clinical malaria incidence, 38 children from each cluster will be enrolled in a cohort and followed for 18 months. We will also evaluate the effects of the intervention on entomological indicators as well as its acceptance by communities and cost-effectiveness.
Ethics and dissemination Ethics approval was provided by the Mount Kenya University Institutional Scientific Ethics Review Committee. Study results will be shared with study participants and communities, the Homa Bay County Government and the Kenya National Malaria Control Programme. Results will also be disseminated through publications, conferences and workshops to help the development of novel malaria control strategies in other malaria-endemic countries.
Trial registration UMIN000053873
Strength and limitations of this study
This study is a cluster-randomized controlled trial (CRCT) to evaluate the efficacy of the Olyset®Plus ceiling net as a novel vector control tool and a complement to current malaria control tools in sub-Saharan Africa.
This marks the second CRCT of the Olyset®Plus ceiling net intervention in the lake endemic region of Kenya, expanding the evidence base to a different eco-epidemiological setting from the previous CRCT, where promising results were observed on Mfangano Island.
Collaboration with local Kenyan institutions such as the Kenya National Bureau of Statistics (KNBS), the National Malaria Control Programme (NMCP), the Kenya Medical Research Institute (KEMRI), and Homa Bay County from the research planning stage is one of the strengths of this trial, allowing for a seamless transition from research implementation in the field to policy development.
One of the anticipated limitations is the possible contamination between intervention and control clusters because we will not set a buffer zone due to the geographical proximity of each cluster. We will try to account for such contamination effects by integrating spatial data into our statistical model.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
UMIN000053873
Funding Statement
YKK and MK were financially supported by the Japan Society for the Promotion of Science. AK and JG received support from JICA/AMED joint research project (SATREPS) (Grant no. 20JM0110020H0002), Hitachi Fund Support for Research Related to Infectious Diseases, and Sumitomo Chemical Corporation. The funding bodies play no role in the study design, data collection, analysis, interpretation, and publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was provided by the Mount Kenya University Institutional Scientific Ethics Review Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study regimes, consent forms, assent forms, and study-related materials are accessible from the corresponding author. The final trial dataset will be available to all investigators. The corresponding author will make the de-identified datasets and source codes for all analysis available upon reasonable request.
Abbreviations
- ACT
- artemisinin-based combination therapy
- CHP
- community health promoter
- CRCT
- cluster-randomized controlled trial
- CV
- coefficient of variation
- kdr
- knockdown resistance
- KHIS
- Kenya Health Information System
- ITN
- insecticide treated nets
- IRS
- indoor residual spraying
- LLIN
- long-lasting insecticidal nets
- MKU
- Mount Kenya University
- PBO
- piperonyl butoxide
- RDT
- rapid diagnosis tests